[144] Metagenomi, Inc. SEC Filing
Metagenomi, Inc. filed a Form 144 notifying a proposed sale of 35,832 common shares through Merrill Lynch on 09/11/2025 on the NASDAQ, with an aggregate market value of $68,080.80. The filing shows the shares were acquired as stock awards from Sarah Noonberg: 26,631 shares on 01/30/2003 and 9,201 shares on 06/05/2025, with payment listed as cash. The issuer has 37,533,136 shares outstanding. The filer reports no sales of the issuer's securities in the past three months and includes the standard signer representation that no undisclosed material adverse information exists.
Metagenomi, Inc. ha presentato un Form 144 notificando una prevista vendita di 35,832 azioni ordinarie tramite Merrill Lynch il 09/11/2025 sul NASDAQ, con un valore di mercato aggregato di $68,080.80. La dichiarazione mostra che le azioni sono state acquisite come premi azionari da Sarah Noonberg: 26,631 azioni il 01/30/2003 e 9,201 azioni il 06/05/2025, con pagamento indicato come cash. L'emittente ha 37,533,136 azioni in circolazione. Il dichiarante segnala di non aver venduto titoli dell'emittente negli ultimi tre mesi e include la tipica rappresentazione del firmatario secondo cui non esistono informazioni materiali avverse non rese note.
Metagenomi, Inc. presentó un Formulario 144 notificando una venta propuesta de 35,832 acciones ordinarias a través de Merrill Lynch el 09/11/2025 en el NASDAQ, con un valor de mercado agregado de $68,080.80. La presentación muestra que las acciones fueron adquiridas como premios en acciones de Sarah Noonberg: 26,631 acciones el 01/30/2003 y 9,201 acciones el 06/05/2025, con el pago indicado como cash. El emisor tiene 37,533,136 acciones en circulación. El presentante reporta no haber vendido valores del emisor en los últimos tres meses e incluye la representación estándar del firmante de que no existen informaciones materialmente adversas no reveladas.
Metagenomi, Inc.은 Merrill Lynch를 통해 NASDAQ에서 09/11/2025에 35,832주 보통주 판매 예정(Form 144)을 제출했으며 총 시가가 $68,080.80입니다. 제출서에 따르면 주식은 Sarah Noonberg의 주식 보상으로 취득되었으며, 26,631주가 01/30/2003에, 9,201주가 06/05/2025에 각각 취득되었고 지급은 cash로 기재되어 있습니다. 발행회사는 37,533,136주를 발행하고 있습니다. 제출자는 지난 3개월 동안 발행자의 증권 매매가 없다고 보고하며, 비공개로 공개되지 않은 중요 악정보가 존재하지 않는다는 서명의 표기를 포함합니다.
Metagenomi, Inc. a déposé un Form 144 signalant une vente proposée de 35,832 actions ordinaires via Merrill Lynch le 09/11/2025 sur le NASDAQ, pour une valeur marchande totale de $68,080.80. Le dépôt indique que ces actions ont été acquises en tant que récompenses d’actions de Sarah Noonberg : 26,631 actions le 01/30/2003 et 9,201 actions le 06/05/2025, le paiement étant indiqué comme cash. L’émetteur compte 37,533,136 actions en circulation. Le déposant déclare ne pas avoir effectué de ventes des valeurs de l’émetteur au cours des trois derniers mois et inclut la représentation standard du signataire selon laquelle il n’existe aucune information substantielle défavorable non divulguée.
Metagenomi, Inc. hat ein Form 144 eingereicht, das einen vorgeschlagenen Verkauf von 35,832 Stammaktien über Merrill Lynch am 09/11/2025 an der NASDAQ meldet, bei einem Gesamtmarktwert von $68,080.80. Die Einreichung zeigt, dass die Aktien als Aktienzuwendungen von Sarah Noonberg erworben wurden: 26,631 Aktien am 01/30/2003 und 9,201 Aktien am 06/05/2025, der Zahlungsausweis lautet cash. Der Emittent hat 37,533,136 ausstehende Aktien. Der Einreicher meldet, dass in den letzten drei Monaten keine Verkäufe von Wertpapieren des Emittenten getätigt wurden, und enthält die Standardunterzeichnererklärung, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen.
قدمت Metagenomi, Inc. نموذج 144 للإخطار ببيع مقترح لـ 35,832 سهماً عادياً عبر Merrill Lynch في 09/11/2025 في NASDAQ، بقيمة سوقية إجمالية قدرها $68,080.80. يظهر الملف أن الأسهم تم الحصول عليها كجوائز أسهم من Sarah Noonberg: 26,631 سهماً في 01/30/2003 و9,201 سهماً في 06/05/2025، مع ذكر الدفع كـ cash. لدى المُصدر 37,533,136 سهماً قائماً. يقر المُقدم بأنه لم يحدث بيع لأسهم المُصدر خلال الثلاثة أشهر الماضية ويتضمن البيان القياسي للموقّع بأن لا وجود لمعلومات سلبية مادية لم تُفصح عنها.
- Complete disclosure of number of shares, acquisition dates, broker, and aggregate market value
- No reported sales in the past three months, indicating this is a discrete, scheduled sale
- Securities provenance listed (stock awards from Sarah Noonberg) and payment method (cash) are specified
- None.
Insights
TL;DR: Routine Rule 144 notice for an insider stock award sale; disclosure is specific with acquisition dates and broker details.
The filing documents a proposed sale of 35,832 common shares via Merrill Lynch with clear acquisition history and cash payment notation. The inclusion of the number of shares outstanding (37,533,136) allows investors to gauge the sale's relative size (approximately 0.095% of outstanding shares). The filing also states no sales in the past three months, which supports the view that this is a scheduled disposition rather than an ongoing trading pattern. As a Form 144, it serves primarily as regulatory transparency rather than a material corporate event.
TL;DR: The notice is a standard insider sale disclosure with explicit provenance of shares and use of a registered broker.
The form identifies the shares as stock awards from a named individual and specifies Merrill Lynch as the executing broker, which aligns with common governance and compliance practices for insider dispositions. The filer reiterates the standard attestation about absence of undisclosed material adverse information. No other governance actions, leadership changes, or related-party transactions are disclosed in this filing.
Metagenomi, Inc. ha presentato un Form 144 notificando una prevista vendita di 35,832 azioni ordinarie tramite Merrill Lynch il 09/11/2025 sul NASDAQ, con un valore di mercato aggregato di $68,080.80. La dichiarazione mostra che le azioni sono state acquisite come premi azionari da Sarah Noonberg: 26,631 azioni il 01/30/2003 e 9,201 azioni il 06/05/2025, con pagamento indicato come cash. L'emittente ha 37,533,136 azioni in circolazione. Il dichiarante segnala di non aver venduto titoli dell'emittente negli ultimi tre mesi e include la tipica rappresentazione del firmatario secondo cui non esistono informazioni materiali avverse non rese note.
Metagenomi, Inc. presentó un Formulario 144 notificando una venta propuesta de 35,832 acciones ordinarias a través de Merrill Lynch el 09/11/2025 en el NASDAQ, con un valor de mercado agregado de $68,080.80. La presentación muestra que las acciones fueron adquiridas como premios en acciones de Sarah Noonberg: 26,631 acciones el 01/30/2003 y 9,201 acciones el 06/05/2025, con el pago indicado como cash. El emisor tiene 37,533,136 acciones en circulación. El presentante reporta no haber vendido valores del emisor en los últimos tres meses e incluye la representación estándar del firmante de que no existen informaciones materialmente adversas no reveladas.
Metagenomi, Inc.은 Merrill Lynch를 통해 NASDAQ에서 09/11/2025에 35,832주 보통주 판매 예정(Form 144)을 제출했으며 총 시가가 $68,080.80입니다. 제출서에 따르면 주식은 Sarah Noonberg의 주식 보상으로 취득되었으며, 26,631주가 01/30/2003에, 9,201주가 06/05/2025에 각각 취득되었고 지급은 cash로 기재되어 있습니다. 발행회사는 37,533,136주를 발행하고 있습니다. 제출자는 지난 3개월 동안 발행자의 증권 매매가 없다고 보고하며, 비공개로 공개되지 않은 중요 악정보가 존재하지 않는다는 서명의 표기를 포함합니다.
Metagenomi, Inc. a déposé un Form 144 signalant une vente proposée de 35,832 actions ordinaires via Merrill Lynch le 09/11/2025 sur le NASDAQ, pour une valeur marchande totale de $68,080.80. Le dépôt indique que ces actions ont été acquises en tant que récompenses d’actions de Sarah Noonberg : 26,631 actions le 01/30/2003 et 9,201 actions le 06/05/2025, le paiement étant indiqué comme cash. L’émetteur compte 37,533,136 actions en circulation. Le déposant déclare ne pas avoir effectué de ventes des valeurs de l’émetteur au cours des trois derniers mois et inclut la représentation standard du signataire selon laquelle il n’existe aucune information substantielle défavorable non divulguée.
Metagenomi, Inc. hat ein Form 144 eingereicht, das einen vorgeschlagenen Verkauf von 35,832 Stammaktien über Merrill Lynch am 09/11/2025 an der NASDAQ meldet, bei einem Gesamtmarktwert von $68,080.80. Die Einreichung zeigt, dass die Aktien als Aktienzuwendungen von Sarah Noonberg erworben wurden: 26,631 Aktien am 01/30/2003 und 9,201 Aktien am 06/05/2025, der Zahlungsausweis lautet cash. Der Emittent hat 37,533,136 ausstehende Aktien. Der Einreicher meldet, dass in den letzten drei Monaten keine Verkäufe von Wertpapieren des Emittenten getätigt wurden, und enthält die Standardunterzeichnererklärung, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen.
قدمت Metagenomi, Inc. نموذج 144 للإخطار ببيع مقترح لـ 35,832 سهماً عادياً عبر Merrill Lynch في 09/11/2025 في NASDAQ، بقيمة سوقية إجمالية قدرها $68,080.80. يظهر الملف أن الأسهم تم الحصول عليها كجوائز أسهم من Sarah Noonberg: 26,631 سهماً في 01/30/2003 و9,201 سهماً في 06/05/2025، مع ذكر الدفع كـ cash. لدى المُصدر 37,533,136 سهماً قائماً. يقر المُقدم بأنه لم يحدث بيع لأسهم المُصدر خلال الثلاثة أشهر الماضية ويتضمن البيان القياسي للموقّع بأن لا وجود لمعلومات سلبية مادية لم تُفصح عنها.
Metagenomi, Inc. 已提交 Form 144，通知拟通过 Merrill Lynch 在 NASDAQ 于 2025-09-11 出售 35,832 股普通股，总市值为 $68,080.80。备案显示这些股票系从 Sarah Noonberg 处获得的股票奖励：26,631 股于 2003-01-30 获得，9,201 股于 2025-06-05 获得，支付方式标注为 cash。发行人流通股数量为 37,533,136 股。申报人报告在过去三个月内未出售发行人证券，并包含签署人标准陈述，即不存在未披露的重大不利信息。
FAQ
What does Metagenomi (MGX) Form 144 notify?
What is the aggregate market value and outstanding shares reported?
When and how were the shares acquired?
Were any shares of the issuer sold by the filer in the past three months?
Which broker is handling the sale?
